Glycosylation is the most abundant posttranslational modification and regulates many biological processes essential to human health ([@r1]), as evidenced by the \>100 congenital disorders of glycosylation discovered to date ([@r2]) and the increasing number of glycosylation-related genes (glycogenes) identified in genomewide association studies in diseases ranging from heart disease ([@r3]) to schizophrenia ([@r4]). However, pinpointing the glycans and their corresponding biosynthetic enzymes controlling specific biological events is a difficult endeavor for two main reasons: (*i*) glycans are an analytical challenge because of their structural complexity and the multiplicity of attachment sites, and (*ii*) glycan biosynthesis requires an intricate pathway with multiple, potentially redundant enzymes (e.g., glycosyltransferases) acting in tandem to create an epitope ([@r5]). Decryption of this complex glycocode would unlock new avenues to control biological interactions.

MicroRNAs (miRNAs) are short noncoding RNAs that repress translation or initiate mRNA degradation through binding to the 3′ UTR of mRNAs ([@r6]). Recent work by our laboratory has shown miRNAs are major regulators of the glycome ([@r7][@r8]--[@r9]). To date 10 human glycogenes have been validated as miRNA targets in the literature ([@r7], [@r8]). In several of these studies, inhibition of the glycogene recapitulates the biological effects of the miRNA ([@r9][@r10]--[@r11]). MiRNAs regulate networks of genes that work in concert to control biological processes ([@r12], [@r13]). We hypothesize that miRNAs controlling a specific biological pathway can be used as a proxy to identify, through its target network, the functionally relevant glycogenes that modulate that biological process.

The cycling of cells between an epithelial (nonmotile) and mesenchymal (migratory) state (epithelial-to-mesenchymal transition, EMT, and mesenchymal-to-epithelial transition, MET) controls embryogenesis and wound healing. Proper orchestration of cell migration is critical during these events, and aberrant EMT is linked to various pathologies including birth defects, cancer metastasis, and fibrosis ([@r14]). MiRNAs are known to play an important role in the regulation of EMT. The miR-200 family (miR-200f) is perhaps the best-characterized miRNA regulator of this process. Levels of mir-200f are high in epithelial cells, low in mesenchymal cells, and regulate expression of Zeb1 (zinc finger E-box binding homeobox 1), a transcription factor that represses E-cadherin ([@r15][@r16]--[@r17]). MiR-200f is regulated by TGF-β, an inducer of EMT ([@r16], [@r17]).

In this work, we leverage the glycogene target network of miR-200f to identify glycosylation enzymes controlling EMT ([@r16], [@r17]). We examine eight glycogenes within the predicted network and validate seven of the eight as targets of miR-200f. We then focus on three genes encoding the difficult-to-study glycans beta-1,3-glucosyltransferase (*B3GLCT*), beta-galactoside alpha-2,3-sialyltransferase 5 (*ST3GAL5*), and (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (*ST6GALNAC5*) and show that, as predicted by the network, they act as regulators of the EMT pathway. Overall, our work provides evidence that miRNA networks can be used to identify key glycosylation enzymes within a biological process, suggesting that miRNA may be used as a proxy to crack the functional glycocode.

Results {#s1}
=======

MiR-200f Targets a Broad Network of Glycogenes. {#s2}
-----------------------------------------------

To identify miR-200f targets, we created a map of miR-200f--glycogene interactions based on conserved and nonconserved miRNA site predictions from miRanda ([Fig. 1*A*](#fig01){ref-type="fig"}) ([@r7]). We considered only glycogene targets with an mirSVR score of −0.1 or less, enhancing the probability of target down-regulation upon miRNA binding ([@r18]). We further simplified our network by focusing on glycosyltransferases. In constructing our network we included the five known members of the miR-200 family: miR-141, -200a, -200b, -200c, and -429. These can be separated into two groups, miR-141/200a and miR-200b/200c/429, within which the miRNAs have an identical seed region. The two groups differ from each other within their seed regions by only one nucleotide ([@r16]). In line with these differences, we observed three clusters of predicted targets, those exclusive to miR-141/200a, those exclusive to miR-200b/200c/429, and those predicted to be targeted by both sets of miRNAs. The predicted glycogene targets were distributed approximately evenly between N*-*linked, O*-*linked (i.e., αGalNAc-Ser/Thr), noncanonical O-linked, and glycolipid biosynthetic pathways with some glycosaminoglycan and terminal modifications also represented, indicating that this family controls a diverse range of glycans ([Table S1](#st01){ref-type="table"}).

![A broad network of glycogenes is targeted by miR-200f. (*A*) Network of predicted glycogene targets for miR-200f. Gray lines connect miRNA to predicted glycogene targets (circles). The size of the circle reflects combined miRSVR scores for all miR-200f predictions. Targets tested by luciferase assay are colored-coded as shown in the key in the figure. (*B*) Graphical representation of luciferase data. Luciferase--3′-UTR reporter constructs were cotransfected with miRNA or scramble mimics (60 nM) in HEK 293T/17 cells. Luciferase signal was assayed 24 h posttransfection. The graphs display average log~2~ (mimic/scramble). *n* = 3 biological replicates; \**P* \< 0.005, *t* test. For wild-type constructs (black bars) displaying a ≥25% decrease (red line), mutants of the appropriate binding region were tested (gray bars; see [Table S2](#st02){ref-type="table"}). [Fig. S1](#sfig01){ref-type="fig"} shows the effect of all five miR-200f members on select constructs. Error bars represent the SD.](pnas.1502076112fig01){#fig01}

###### 

Classification of predicted miR-200f target glycogenes according to the type of glycan synthesized (related to [Table S3](#st03){ref-type="table"})

             N-linked   O-linked   NC-O--linked   GAGs       Glycolipid   Other/terminal
  ---------- ---------- ---------- -------------- ---------- ------------ ----------------
             ALG2       C1GALT1    B3GAT1         B3GALT6    B3GALT2      B3GALNT2
             ALG5       GALNT2     B3GLCT         CHSY3      B3GALNT1     B3GNT1
             ALG6       GALNT3     GXYLT1         HS3ST1     B3GNT4       B3GNT2
             ALG8       GALNT4     HAS2           HS3ST3A1   B3GNT5       FUT2
             ALG11      GALNT10    LARGE          HS6ST2     B4GALT6      FUT4
             DDOST      GALNT11    LFNG                      CSGALNACT2   ST3GAL2
             MGAT2      GALNT12    MGEA5                     GAL3ST1      ST3GAL3
             MGAT3      GALNT14    OGT                       ST3GAL5      ST8SIA2
             MGAT4A     GCNT4      POFUT1                    ST3GAL6      ST8SIA4
             MGAT4C                                          ST6GALNAC3   
                                                             ST6GALNAC5   
                                                             UGCG         
  Count      10.0       9.0        9.0            5.0        12.0         9.0
  \% total   18.5       16.7       16.7           9.3        22.2         16.7

miR-200f predicated glycogenes were classified according to the glycan they synthesize using the Kyoto Encyclopedia of Genes and Genomes. The % total represents the distribution of one type of glycan among all predicted targets. GAGs, glycosaminoglycans; NC-O--linked, noncanonical O-linked.

We selected eight targets within the miRNA--glycogene network for validation using a 3′-UTR--luciferase reporter assay ([Fig. 1](#fig01){ref-type="fig"}). MiRNA mimics that repressed luciferase expression by ≥25% \[log~2~(mimic/scramble) = −0.42; red line in [Fig. 1*B*](#fig01){ref-type="fig"}\] were considered significant inhibitors of the glycogene. miRNA-binding sites were validated by mutagenesis of the seed-binding regions of the 3′-UTR--luciferase constructs ([Fig. 1*B*](#fig01){ref-type="fig"} and [Table S2](#st02){ref-type="table"}). MiRNA mimics of miR-141, -200c, and -429 gave results similar to those of other members within their group ([Fig. S1](#sfig01){ref-type="fig"}). Of the eight targets tested, only *MGAT2* was not targeted by miR-200f. In addition, two genes predicted to be targets of all family members, *B3GLCT* and *ST3GAL5*, were targeted only by miR-200b/200c/429 ([Fig. 1*B*](#fig01){ref-type="fig"} and [Fig. S1](#sfig01){ref-type="fig"}). Overall, our data confirmed multiple miR-200f--glycogene interactions and identified clear differences in the ability of the two distinct groups of miR-200f members to target glycogenes.

###### 

Summary of seed region mutations in 3′ UTRs used in luciferase assay (related to [Fig. 1](#fig01){ref-type="fig"})

  ------------------------------
  ![](pnas.1502076112st01.jpg)
  ------------------------------

![Members of the two miR-200f groups have similar effects on their targets. Graphical representation of luciferase assays showing the effects of all miR-200f members on *B3GLCT*, *HS6ST2*, *ST3GAL5*, and *ST6GALNAC5* 3′-UTR constructs. The assays were performed as indicated in [Fig. 1](#fig01){ref-type="fig"}. The graphs display average log~2~ (mimic/scramble). *n* = 3 biological replicates; \**P* \< 0.005, Student's *t*-test. For wild-type constructs (black bars) displaying ≥25% decrease (red line), mutants of the appropriate binding region were tested (gray bars; see [Table S2](#st02){ref-type="table"}). Error bars represent SD.](pnas.1502076112sfig01){#sfig01}

MiR-200f Regulates the Glycome in MDA-MB-231 Cells Undergoing MET. {#s3}
------------------------------------------------------------------

MiR-200f levels are high in epithelial cells, which express high levels of E-cadherin, form tight junctions, and have low motility. Conversely, miR-200f is low in mesenchymal cells, which lose cell--cell contacts and are characterized by low levels of E-cadherin and high motility ([@r16], [@r17]). The highly metastatic breast cancer cell line MDA-MB-231 is considered mesenchymal and is commonly used to examine MET ([@r12], [@r17]). MiR-200f is known to cause MET within this cell line ([@r12], [@r17], [@r19]). Previous reports have not distinguished clearly between the effects of the two miR-200f groups, often using combinations of miRNAs from both sets. Our luciferase data suggest that the two miR-200f groups have disparate effects on the glycome. Transfection of MDA-MB-231 cells with either miR-200a or -200b mimics induced changes in morphology consistent with MET, but these changes were more apparent in miR-200b--treated cells ([Fig. 2*A*](#fig02){ref-type="fig"}). This observation was confirmed by examination of MET markers. The expected increase in E-cadherin and loss of vimentin and *ZEB1* expression were observed in both miRNA treatments but were more pronounced for cells treated with miR-200b mimics ([Fig. 2 *B* and *C*](#fig02){ref-type="fig"} and [Fig. S2*A*](#sfig02){ref-type="fig"}).

![MiR-200f regulates glycosylation in MDA-MB-231 cells undergoing MET. (*A*) Representative phase-contrast images of MDA-MB-231 cells treated with scramble, miR-200a, or miR -200b mimics (50 nM, 7 d). The morphology is consistent with the induction of MET by miRNA. (*B*) Western blot analysis of the EMT markers E-cadherin (epithelial) and vimentin (mesenchymal) from MDA-MB-231 cells treated as in *A*. Data shown are representative of four biological replicates. (*C*) Relative abundance of mRNA for the EMT markers E-cadherin and vimentin from MDA-MB-231 cells treated as in *A*. qRT-PCR data are reported as the average of the relative expression in four biological replicates normalized to *GAPDH*. Error bars denote SD; \**P* \< 0.005, *t* test. (*D*--*F*) Glycan epitopes biosynthesized by *B3GLCT* (*D*), *ST3GAL5* (*E*), and *ST6GALNAC5* (*F*). (*G--I*) Relative abundance of mRNA encoding *B3GLCT*, *ST3GAL5*, and *ST6GALNAC5* shows changes in transcript expression with MET. Analysis was on samples from *C* using the same methods. *n* = 4; \**P* \< 0.005; \*\**P* \< 0.02, *t* test. (*J*--*L*) Western blot analysis shows a decrease in B3GLCT (*J*), ST3GAL5 (*K*), and ST6GALNAC5 (*L*) protein levels with MET. Samples from *B* were used. Representative images from four biological replicates are shown. (*M*) MDA-MB-231 cells undergoing MET lose GM3. MDA-MB-231 cells were treated as in *A*, fixed with paraformaldehyde, and stained for GM3 (see [*SI Experimental Procedures*](#si1){ref-type="sec"} for details). Phase-contrast and fluorescence images representative of two biological replicates (four images per replicate) are shown. Scr, scramble.](pnas.1502076112fig02){#fig02}

![Effects of miR-200f and glycogene silencing on *ZEB1*. (*A*) miR-200b has a more pronounced effect than mir-200a on EMT. MDA-MB-231 cells were treated with scramble, miR-200a, or miR-200b mimics (50 nM, 7 d) and analyzed by qRT-PCR. qRT-PCR data for ZEB1 are reported as the average of relative expression of four biological replicates normalized to *GAPDH*. Error bars denote SD; \**P* \< 0.005, *t* test. (*B*) Effect of glycogene silencing on *ZEB1* Levels. Data are from MDA-MB-231 cells treated with control shRNA or shRNAs silencing (KO) *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5* on day 5 (control, *B3GLCT*, and *ST3GAL5*), or day 10 (*ST6GALNAC5*) after treatment. qRT-PCR data are reported as the average of relative expression of three biological replicates normalized to *GAPDH*. Error bars denote SD; \**P* \< 0.05.](pnas.1502076112sfig02){#sfig02}

We next examined the effects of miR-200a or -200b treatment on the expression of predicted mir-200f glycogene targets by quantitative RT-PCR (qRT-PCR) ([Table S3](#st03){ref-type="table"}). Overall, we found a larger number of predicted glycogenes altered in the miR-200b--treated samples (miR-200a: 8/33; miR-200b: 15/33), indicating that miR-200b has a more profound effect on the glycome in this system. In examining the data, we noticed that none of the glycogenes exclusive to the N-linked pathway was affected significantly by either miRNA. Lectin microarray analysis of miR-200a-- and -200b--treated cells showed no changes in N*-*linked--specific lectin binding ([Fig. S3](#sfig03){ref-type="fig"}), in line with our mRNA expression ([Table S3](#st03){ref-type="table"}) and luciferase ([Fig. 1*B*](#fig01){ref-type="fig"}) data. In general, few changes were observed on our lectin microarrays, which have limited analytical capacity for glycolipids, glycosaminoglycans, and noncanonical O-links (i.e., the majority of miR-200f targets). In light of these data, we focused our attention on three specific glycogenes in the miR-200b network from the glycolipid and noncanonical O-linked pathways: *B3GLCT*, which catalyzes the addition of a glucose to O*-*fucosylated serines and threonines; *ST3GAL5*, a sialyltransferase that modifies the glycolipid lactosylceramide to form GM3; and *ST6GALNAC5*, which transfers a sialic acid to the *N-*acetylgalactosamine on the glycolipid GM1b to form GD1α ([Fig. 2 *D*--*F*](#fig02){ref-type="fig"}, respectively) ([@r20]).

###### 

miR-200f target glycogene transcript expression profile in MDA-MB-231 cells treated with miR-200a, miR-200b, or scramble mimics

  miR-200a treatment                                       miR-200b treatment   Glycan type                                                                                            
  -------------------------------------------------------- -------------------- -------------- ------------------------------------------------------- ------------- ----------------- ----------------
  Shared predicted targets                                                                                                                                                             
   *MGAT4A*                                                1.06                 0.74           *MGAT4A*                                                1.17          0.31              N-linked
   ***C1GALT1***                                           **−1.19**            **0.050**      *C1GALT1*                                               −1.10         0.40              O-linked
   ***GALNT14***                                           **−1.49**            **0.011**      ***GALNT14***                                           **−1.94**     **0.0059**        
   [*\**](#tfn1){ref-type="table-fn"}*B3GLCT*              −1.06                0.69           [***\****](#tfn1){ref-type="table-fn"}***B3GLCT***      **−1.61**     **0.0042**        NC O-linked
   [***\****](#tfn1){ref-type="table-fn"}***ST3GAL5***     **−1.61**            **0.0064**     [***\****](#tfn1){ref-type="table-fn"}***ST3GAL5***     **−2.13**     **2.1E-0.4**      Glycolipid
   *ST6GALNAC3*                                            1.62                 0.20           *ST6GALNAC3*                                            1.11          0.76              
   *B3GNT2*                                                1.07                 0.66           *B3GNT2*                                                1.22          0.15              Other/terminal
  miR-200b/-200c/-429 predicted targets                                                                                                                                                
   [*\**](#tfn1){ref-type="table-fn"}*MGAT2*               −1.08                0.72           [*\**](#tfn1){ref-type="table-fn"}*MGAT2*               1.01          0.98              N-linked
   *MGAT3*                                                 −1.86                0.12           *MGAT3*                                                 1.30          0.15              
   *MGAT4C*                                                1.93                 0.20           *MGAT4C*                                                −1.00         1.00              
   *GALNT2*                                                −1.09                0.52           ***GALNT2***                                            **−1.40**     **0.022**         O-linked
   *GALNT3*                                                1.03                 0.71           *[GALNT3]{.ul}*                                         [2.30]{.ul}   [4.5E-0.4]{.ul}   
   *GALNT10*                                               −1.14                0.11           ***GALNT10***                                           **−1.68**     **0.0012**        
   *GALNT11*                                               −1.11                0.29           ***GALNT11***                                           **−1.26**     **0.011**         
   ***GALNT12***                                           **−1.40**            **0.0074**     ***GALNT12***                                           **−1.52**     **0.0063**        
   *GCNT4*                                                 −1.18                0.16           *GCNT4*                                                 −1.05         0.79              
   *LFNG*                                                  −1.49                0.21           *LFNG*                                                  −2.14         0.074             NC O-linked
   *MGEA5*                                                 −1.06                0.58           *MGEA5*                                                 1.02          0.71              
   *CHSY3*                                                 1.15                 0.36           *CHSY3*                                                 −1.04         0.68              GAGs
   *[HS3ST1]{.ul}*                                         [1.99]{.ul}          [0.044]{.ul}   *[HS3ST1]{.ul}*                                         [3.28]{.ul}   [0.014]{.ul}      
   *HS3ST3A1*                                              −1.11                0.74           *HS3ST3A1*                                              −1.24         0.39              
   *B3GALNT1*                                              −1.11                0.56           *B3GALNT1*                                              −1.16         0.46              Glycolipid
   [*\**](#tfn1){ref-type="table-fn"}*[ST6GALNAC5]{.ul}*   [2.23]{.ul}          [0.033]{.ul}   [*\**](#tfn1){ref-type="table-fn"}*[ST6GALNAC5]{.ul}*   [4.79]{.ul}   [0.010]{.ul}      
   *B3GNT1*                                                −1.04                0.80           ***B3GNT1***                                            **−1.47**     **0.039**         Other/terminal
   *ST3GAL2*                                               −1.18                0.20           ***ST3GAL2***                                           **−1.59**     **0.0012**        
   ***ST8SIA4***                                           **−1.23**            **0.013**      *ST8SIA4*                                               −1.15         0.22              
  miR-200a/141 predicted targets                                                                                                                                                       
   *GALNT4*                                                −1.16                0.20           *GALNT4*                                                −1.17         0.077             O-linked
   *POFUT1*                                                −1.00                0.98           *POFUT1*                                                −1.01         0.90              NC O-linked
   *B3GALT6*                                               1.05                 0.83           *B3GALT6*                                               1.00          0.99              GAGs
   *B3GNT4*                                                1.29                 0.075          *[B3GNT4]{.ul}*                                         [2.24]{.ul}   [6.4E-04]{.ul}    Glycolipid
   *B3GNT5*                                                1.25                 0.11           *[B3GNT5]{.ul}*                                         [1.70]{.ul}   [0.0026]{.ul}     
   [*\**](#tfn1){ref-type="table-fn"}*ST3GAL6*             −1.18                0.30           [*\**](#tfn1){ref-type="table-fn"}*ST3GAL6*             1.01          0.91              
   [***\****](#tfn1){ref-type="table-fn"}***ST3GAL3***     **−1.42**            **0.051**      [***\****](#tfn1){ref-type="table-fn"}***ST3GAL3***     **−1.43**     **0.035**         Other/terminal

MDA-MB-231 cells were treated with miR-200a, miR-200b, or scramble mimics (50 nM) for 7 d. qRT-PCR was performed using RT^2^ Profiler PCR Array Human Glycosylation (Qiagen) or custom primers for genes not represented on the array ([Dataset S1](#d35e1631){ref-type="supplementary-material"}). Fold change (miR-treated/scramble) was calculated by taking the average relative expression of miR-treated samples (*n* = 4 independent experiments, normalized to GAPDH) over the average relative expression of the scramble-treated cells (*n* = 4 independent experiments, normalized to GAPDH). Where the fold change was less than 1, the negative inverse is shown. *P* values for treated vs. scramble were calculated using Student\'s *t*-test. Statistically significant (*P* ≤ 0.05) down-regulation is in bold; up-regulation is underlined. GAGs, glycosaminoglycans; NC O-linked, noncanonical O-linked; See [Table S1](#st01){ref-type="table"} for glycan type distribution.

Genes for which luciferase data were obtained ([Fig. 1](#fig01){ref-type="fig"}).

![Glycomic analysis of MDA-MB-231 cells treated with miR-200f. Lectin microarray analysis of MDA-MB-231 cells treated as in [Fig. 2*A*](#fig02){ref-type="fig"}. In brief, equal amounts of Cy5-sample (S) and Cy3-reference (R) were analyzed on the lectin microarray. The heat map shows the median-normalized log~2~ ratios (S/R). Hierarchical clustering used the centered Pearson correlation coefficient as the distance metric and average linkage analysis (*n* = 77 lectins). Red, log~2~(S/R) \> log~2~(S~median~/R~median~); green, log~2~(S~median~/R~median~) \> log~2~(S/R). A yellow box indicates lectins that are significantly different between miR-200f and scramble treatment (*P* \< 0.05, *t* test, *n* = 3). Lectins specific to N-linked glycans are denoted in blue. [Table S1](#st01){ref-type="table"} shows miR-200f glycogene target classification based on glycan type. [Dataset S1](#d35e1631){ref-type="supplementary-material"} shows the printlist for the microarray.](pnas.1502076112sfig03){#sfig03}

Our candidate genes were chosen for three reasons: (*i*) all three displayed \>40% down-regulation by miR-200b in our luciferase assays ([Fig. 1*B*](#fig01){ref-type="fig"}); (*ii*) all three were associated with human disease ([@r3], [@r21][@r22][@r23]--[@r24]); (*iii*) all three glycogenes showed significant changes in mRNA expression levels in miR-200b--treated MDA-MB-231 cells undergoing miRNA-induced MET (*P* ≤ 0.01) ([Table S3](#st03){ref-type="table"}). Unlike *B3GLCT* and *ST3GAL5*, the expression of *ST6GALNAC5* mRNA increased in the miR-200b--treated samples ([Fig. 2 *G*--*I*](#fig02){ref-type="fig"}). This finding is in contrast to both the luciferase data for the *ST6GALNAC5* 3′-UTR construct ([Fig. 1*B*](#fig01){ref-type="fig"}) and protein expression levels, which were repressed for all three enzymes by miR-200b ([Fig. 2 *J*--*L*](#fig02){ref-type="fig"}). It is common for miRNA to repress translation in the absence of an mRNA degradation effect ([@r6]), as is observed here for *ST6GALNAC5*. To determine whether glycans synthesized by these glycogenes were down-regulated by miR-200b, we used fluorescence microscopy to examine the levels of GM3, the glycolipid product of *ST3GAL5* ([Fig. 2*E*](#fig02){ref-type="fig"}), in response to miR-200b treatment ([Fig. 2*M*](#fig02){ref-type="fig"}). We observed a clear loss of anti-GM3 antibody staining for miR-200b--treated MDA-MB-231 cells, as would be expected. Taken together, our data show that miR-200f alters the glycome by targeting glycogenes in MDA-MB-231 cells undergoing miRNA-induced MET.

Silencing B3GLCT, ST3GAL5, or ST6GALNAC5 Phenocopies the Effects of miR-200b in MDA-MB-231 Cells. {#s4}
-------------------------------------------------------------------------------------------------

To examine whether glycogenes targeted by miR-200b are directly involved in EMT, we silenced *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5* in MDA-MB-231 cells using shRNA. If these genes are involved in the EMT pathway, silencing them should phenocopy the effects of miR-200b, driving MET forward in the mesenchymal cell line. Morphological changes indicative of MET were observed as early as 5 d following lentiviral vector transduction and selection for shRNA-expressing cells ([Fig. 3*A*](#fig03){ref-type="fig"}). We evaluated E-cadherin expression in *B3GLCT*- and *ST3GAL5*-silenced cells at day 5 and, because of slower growth rates, in *ST6GALNAC5*-silenced cells at day 10 ([Fig. 3](#fig03){ref-type="fig"} and [Fig. S4](#sfig04){ref-type="fig"}). Gene silencing resulted in increased expression of E-cadherin at both the protein and transcript levels, in line with the observed morphological changes. *ZEB1* levels also were increased in all three knockdowns, indicating that the increase in E-cadherin is not caused by repression of this transcriptional regulator ([Fig. S2*B*](#sfig02){ref-type="fig"}).

![Silencing *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5* phenocopies miR-200b, inducing MET in MDA-MB-231 cells. (*A*) Representative phase-contrast images of MDA-MB-231 cells treated with control shRNA or shRNAs silencing (KO) *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5*. Images were acquired on day 5 (control, *B3GLCT, ST3GAL5*) or day 10 (*ST6GALNAC5*) after treatment. [Fig. S4](#sfig04){ref-type="fig"} shows day 10 images for control and expanded fields of view for the images shown. Images are representative of a minimum of three biological replicates with three fields of view per experiment. (*B*, *D*, and *F*) qRT-PCR analysis of MDA-MB-231 cells treated as in *A*. Glycogene mRNA confirms shRNA silencing (KO) compared with control for *B3GLCT* (*B*), *ST3GAL5* (*D*), and *ST6GALNAC5* (*F*) and an increase in E-cadherin mRNA. qRT-PCR data are reported as the average relative expression of four (*B3GLCT*, *ST3GAL5*) or three (*ST6GALNAC5*) biological replicates normalized to *GAPDH*. Error bars denote SD; \**P* \< 0.002; \*\**P* \< 0.02; *t* test. (*C*, *E*, and *G*) Western blot analysis shows an increase in E-cadherin levels induced by shRNA silencing of *B3GLCT* (*C*), *ST3GAL5* (*E*), or *ST6GALNAC5* (*G*). Western blot samples were collected on day 5 (B3GLCT) or day 10 (ST3GAL5 and ST6GALNAC5). Representative blots from three (ST3GAL5 and ST6GALNAC5) or four (B3GLCT) biological replicates are shown.](pnas.1502076112fig03){#fig03}

![Effect of glycogene silencing on MDA-MB-231 morphology. (*A*) Representative phase-contrast images of MDA-MB-231 cells treated with control or shRNA against *ST6GALNAC5* on day 10 posttreatment. (*B*) Original uncropped images corresponding to those shown in [Fig. 3*A*](#fig03){ref-type="fig"}. Yellow boxes indicate regions selected for [Fig. 3*A*](#fig03){ref-type="fig"}.](pnas.1502076112sfig04){#sfig04}

MiR-200f regulates not only the morphology but also the migratory capacity of cells ([@r12], [@r19]). Previous studies have shown that miR-200f expression in MDA-MB-231 cells inhibits the migration of this cell line in wound-healing assays ([@r12], [@r19]). To test whether silencing *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5* mimics the effects of miR-200b on the migratory capacity of MDA-MB-231 cells, we performed in vitro scratch assays ([@r25]). Migration was evaluated after 24 h, which is less than the doubling time of MDA-MB-231 cells ([@r26]). As expected, transfection of MDA-MB-231 cells with miR-200b mimics inhibited gap closure in the scratch assay as compared with a scrambled control (46% of control, *P* = 0.01) ([Fig. 4 *A* and *B*](#fig04){ref-type="fig"}). Silencing of *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5* recapitulated the inhibition of migration observed with miR-200b (*P* \< 0.001 for *B3GLCT* and *ST6GALNAC5*; *P* = 0.02 for *ST3GAL5*) ([Fig. 4 *C* and *D*](#fig04){ref-type="fig"}). The strongest effect was observed in the *B3GLCT* knockdown (20% of control). Migration was reduced to 38% of control in *ST6GALNAC5*-silenced cells and to 67% of control in *ST3GAL5*-silenced cells. Thus, silencing glycogenes targeted by miR-200b phenocopies the effects of the miRNA, suggesting that miR-200f regulates glycosylation enzymes that are important components of the biological pathways it controls.

![Silencing *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5* phenocopies miR-200b, inhibiting migration in scratch assays. (*A*) Representative phase-contrast images show reduced migration of MDA-MB-231 cells treated with miR-200b mimic (50 nM). Scrambled mimic (Scramble) served as control. Scratches were made with a P200 tip on plates at 100% confluency 6 d posttransfection and were imaged (0 h). The identical region was imaged 24 h later to determine the extent of wound healing. Images are representative of three biological replicates. (*B*) Graphical representation of the percent of closure in the experiments in *A*. Images were analyzed in ImageJ, and the wound area was calculated for 0 h and 24 h postscratch. Graphs show the average percent of closure for the three biological replicates. Error bars denote SD; \*\**P* \< 0.05; *t* test. (*C*) Representative phase-contrast images show reduced migration of cells treated with shRNAs silencing (KO) *B3GLCT*, *ST3GAL5*, or *ST6GALNAC5*. Scratches were made with a P200 tip on plates at 100% confluency 5 d post shRNA treatment (glycogene or control) and were imaged (0 h). The identical region was imaged 24 h later to determine the extent of wound healing. Images are representative of three biological replicates. (*D*) Graphical representation of the percent of closure for the experiments in *C*. Images were analyzed as in *B*. Graphs show the average percent of closure for three biological replicates. Error bars denote SD; \**P* \< 0.001, \*\**P* \< 0.05; *t* test.](pnas.1502076112fig04){#fig04}

TGF-β1 Induces Both EMT and Increased Protein Expression of B3GLCT, ST3GAL5, and ST6GALNAC5 in A549 Cells. {#s5}
----------------------------------------------------------------------------------------------------------

We tested whether *B3GLCT*, *ST3GAL5*, and *ST6GALNAC5* were involved in the more complex EMT networks induced by a natural stimulus of EMT, TGF-β1. TGF-β1 is a cytokine known to induce EMT, in part through up-regulation of the transcription factor Zeb1, a repressor of both miR-200f and E-cadherin ([@r16], [@r27]). We examined the effects of TGF-β1 on A549 cells, a human nonsmall cell lung carcinoma line that has been used previously to study TGF-β1--induced EMT ([@r28]). In brief, cells were treated with TGF-β1 (5 ng/mL) for 48 h. Changes in morphology consistent with EMT could be observed as soon as 24 h after treatment. By 48 h, the majority of cells displayed the spindle-shaped morphology characteristic of a mesenchymal phenotype ([Fig. 5*A*](#fig05){ref-type="fig"}). Analysis of E-cadherin, fibronectin (a mesenchymal marker), vimentin, and Zeb1 by qRT-PCR in these cells confirmed the induction of EMT ([Fig. 5*B*](#fig05){ref-type="fig"}). We analyzed the expression of *B3GLCT*, *ST3GAL5*, and *ST6GALNAC5* transcripts in these cells ([Fig. 5*C*](#fig05){ref-type="fig"}). Because of the very low expression levels of the *ST6GALNAC5* mRNA, we were not able to determine changes in this transcript by qRT-PCR. Both *B3GLCT* and *ST3GAL5* showed significant increases in expression (3.5-fold and 1.5-fold, respectively) compared with untreated cells. We observed increases in protein expression levels consistent with the changes in glycogene mRNA ([Fig. 5*D*](#fig05){ref-type="fig"}). By loading threefold more protein than was used in the Western blot analysis of B3GLCT and ST3GAL5, we were able to observe an increase in ST6GALNAC5 protein expression because of TGF-β1--induced EMT. Overall our results suggest that glycogenes targeted by miR-200b are promesenchymal genes that are part of the broader EMT-signaling network induced by TGF-β1.

![TGF-β1 induces both EMT and increased protein expression of B3GLCT, ST3GAL5, and ST6GALNAC5 in A549 cells. (*A*) Representative phase-contrast images of A549 cells undergoing EMT induced by treatment with TGF-β1 (5 ng/mL, 48 h). Vehicle-treated cells (Veh) are shown as a control. (*B*) Relative abundance of mRNA encoding the EMT markers E-cadherin, fibronectin, vimentin, and Zeb1 in A549 cells treated as in *A*. qRT-PCR data are reported as the average of relative expression normalized to *GAPDH*. Error bars denote SD; \**P* \< 0.005; *t* test; *n* = 3 biological replicates. (*C*) Relative abundance of mRNA encoding glycogenes *B3GLCT* and *ST3GAL5* in the samples used in *B*. qRT-PCR data are reported as the average of relative expression normalized to *GAPDH*. Error bars denote SD; \**P* \< 0.002; \*\**P* \< 0.01; *t* test; *n* = 3 biological replicates. (*D*) Western blot data for samples used in *B* and *C* show a decrease in E-cadherin and a concomitant increase of B3GLCT, ST3GAL5, and ST6GALNAC5 protein levels. To visualize ST6GALNAC5, threefold-higher sample levels (60 μg protein) were evaluated. Representative data from the three biological replicates are shown.](pnas.1502076112fig05){#fig05}

SI Experimental Procedures {#si1}
==========================

GM3 Staining. {#si2}
-------------

MDA-MB-231 cells were transfected with miRNA mimics as previously described. After the second transfection (72 h after the initial treatment), cells were split into glass-bottomed dishes (35 × 20 mm; In Vitro Scientific) coated with gelatin (0.8 µL/cm^2^, 2% gelatin solution; Sigma Aldrich) and cultured for an additional 3 d. Cells then were fixed in 4% (wt/vol) paraformaldehyde in HBSS (10 min, room temperature) and incubated with α-GM3 antibody (1:100 vol/vol in HBSS, 1 h, 37 °C) (clone M2590; Cosmo Bio Co, Ltd.), followed by α-mouse--Alexa Fluor-647 (1:100 vol/vol in PBS solution, 30 min, 37 °C) (Invitrogen) in the dark. Samples were imaged by fluorescence microscopy (60× PlanFluor objective, NA 0.3, excitation/emission, 625--650 nm/670 nm, Eclipse TE 2000-U; Nikon). All fluorescence images within an experiment were acquired under identical conditions.

Lectin Microarray. {#si3}
------------------

MDA-MB-231 cells were treated with miRNA 200a, -200b, or scramble mimics for 7 d as previously described. Cell sample preparation and lectin microarray analysis then were conducted as previously described ([@r45]). Briefly, cell membrane samples were prepared and labeled with NHS-Cy5. Reference was prepared by mixing equal amounts (by protein) of membrane samples from MDA-MB-231 cells treated with scramble, mir-200a, or mir-200b before labeling with NHS-Cy3. Lectins were purchased from E. Y. Laboratories or Vector Laboratories with the following exceptions: recombinant cyanovirin, scytovirin, and griffithsin were gifts from B. O'Keefe (Frederick National Laboratory for Cancer Research, Frederick, MD); recombinant Gaf-D, PA-IL, PA-IIL, and RS-IIL were made as previously described ([@r46]); TJA-I and TJA-II were from NorthStar Bioproducts; and PA-I was from Sigma Aldrich. Antibodies were purchased from Santa Cruz Biotechnology (SPM110, P12, 7LE), R&D Systems (Lewis x), and Abcam (F3). [Dataset S1](#d35e1631){ref-type="supplementary-material"} summarizes the printlist. Printing, hybridization, and data analysis were performed as previously described ([@r47]). Our data were distributed normally as determined by the Lilliefors test. Lectins were excluded from analysis if they did not meet our minimal threshold for activity ([@r48]).

Discussion {#s6}
==========

Glycosylation can impact many aspects of the cell, from cell adhesion to receptor clustering and activation ([Fig. 6](#fig06){ref-type="fig"}). For example, glycosylation of E-cadherin, fibronectin, and other EMT-associated glycoproteins governs their roles in adhesion and motility, altering their stability and protein-interaction networks ([@r29][@r30]--[@r31]). A single glycosylation enzyme can regulate multiple components of a biological pathway, exerting a synergistic effect. Current approaches to identifying functionally relevant glycans are focused on glycan analysis to identify glycans that alter in disease and on glycogene profiling to identify changes in mRNA that correlate with disease states. These approaches have several limitations. (*i*) High-throughput analysis of glycans typically is not comprehensive ([@r5]). The great majority of studies on glycans in disease focus on only the N*-*linked glycome. Glycolipids, O-linked glycans, and glycosaminoglycans often are ignored because of difficulties in sample preparation and annotation in mass spectrometry and a lack of specific binding reagents. (*ii*) Glycogene transcripts often are at the limits of detection, where quantitation is inaccurate, complicating mRNA profiling ([@r32], [@r33]). (*iii*) The multiple glycosylation enzymes with overlapping catalytic specificities present a challenge in mapping changes in glycan structure to changes in specific enzyme levels ([@r34]). (*iv*) It is not clear that all changes in glycosylation correlating with a disease state or biological process are relevant. Some alterations may be bystanders of the expression of other functionally relevant glycans ([@r35]). Identifying the parts of the glycocode that are meaningful in terms of biological function in a specific system is more complex than simply identifying changes in glycosylation.

![The MiR-200 family regulates a network of glycogenes altering glycosylation crucial to processes involved in EMT. Glycogenes inhibited when miR-200f levels are high (*Left*, green arrow, red glycogenes) and promoted by loss of miR-200f (*Right*, red arrow, green glycogenes) alter glycosylation in multiple contexts including receptor signaling ([@r36]), protein secretion ([@r40]), and cell-adhesion networks ([@r29][@r30]--[@r31]).](pnas.1502076112fig06){#fig06}

In this work we demonstrate a previously undescribed strategy for decrypting the functional glycocode that leverages miRNA as a proxy for identifying glycosylation enzymes that are important for a specific biological process, EMT ([Fig. 6](#fig06){ref-type="fig"}). By leveraging miR-200f target networks ([Fig. 1](#fig01){ref-type="fig"}), we identified a set of relevant glycogenes from the cohort that biosynthesize glycans ignored in typical glycan analysis. MiR-200f strongly impacted glycogenes controlling glycolipid, glycosaminoglycan, and O-linked glycan biosynthesis ([Table S3](#st03){ref-type="table"}), which comprise 65% of predicted targets ([Table S1](#st01){ref-type="table"}), rather than the N*-*linked--associated glycogenes that are the focus of most research. Our miRNA strategy bypasses the analytical constraints attached to glycolipids, glycosaminoglycans, and O-linked glycans to identify specific glycosylation enzymes and, by extension, the epitopes they biosynthesize as modulators of the EMT pathway.

From the broader miR-200f network, we focused our studies on three targets: *B3GLCT*, *ST6GALNAC5*, and *ST3GAL5*, which biosynthesize noncanonical O*-*linked glycans and glycolipids ([Fig. 2 *D*--*F*](#fig02){ref-type="fig"}). Knocking down any of these three glycogenes phenocopied the known effects of miR-200f, reversing the mesenchymal phenotype, increasing E-cadherin, and slowing cell migration. These effects were not mediated by the transcription factor Zeb1, indicating that these glycans affect protein expression and/or stabilization of E-cadherin independent of the transcriptional repressor. Induction of EMT by TGF-β1 increased the expression of all three glycosylation enzymes. This finding is in line with the known function of TGF-β, which inhibits mir-200f. Taken together, our data demonstrate that miR-200f controls glycosylation enzymes that are functionally relevant to EMT and that miRNA can be used as a proxy to place these enzymes into biological context.

Placing glycogenes into context within specific pathways using miRNA as a predictor may offer insight into the roles of glycosylation in human disease. MiR-200f is a regulatory component of the TGF-β EMT-signaling pathway, implying that *B3GLCT, ST6GALNAC5*, and *ST3GAL5* also are components of that pathway. Increased levels of the glycolipid GM3, the product of *ST3GAL5*, have been shown to promote the dimerization and activation of TGF-β receptors ([@r36]). However, *B3GLCT* and *ST6GALNAC5* are not known to be involved in EMT. Mutations that compromise the enzymatic activity of *B3GLCT*, the β1,3-glucosyltranferase previously annotated as *B3GALTL*, are the underlying cause of Peter\'s Plus syndrome ([@r21]), a congenital disorder characterized by malformation of the eye (Peter\'s anomaly), short stature, and craniofacial features commonly including cleft palate ([@r37]). TGF-β--induced EMT plays a predominant role in both the formation of the eye ([@r38]) and the closure of the palate during embryonic development ([@r39]), and recent work has implicated *B3GLCT* in the secretion of thrombospondin-1, a protein involved in TGF-β activation ([@r40]). Taken together, this report and our data suggest that Peter\'s Plus is a TGF-β--related EMT-disruption syndrome, similar to other congenital disorders with TGF-β--related mechanisms ([@r41]). Coronary artery disease (CAD) caused by activating mutations in *ST6GALNAC5* ([@r3]) also may be related to TGF-β--induced EMT. CAD has been linked to higher TGF-β levels ([@r42]) and fibrosis, an EMT process ([@r43]). Thus, higher *ST6GALNAC5* activity may promote TGF-β signaling, causing CAD. If these rare genetic mutations do impact TGF-β networks, drugs that target TGF-β signaling potentially could help patients with these syndromes, effectively deorphanizing these diseases by placing them in the larger context of TGF-β--related disorders.

Identifying functionally relevant glycosylation enzymes opens new avenues for therapeutics for virtually any disease ([@r1]). Glycosylation enzymes are overlooked as druggable targets because of the difficulties in pinpointing the critical enzymes in a disease state ([@r34], [@r35], [@r44]). However, glycans play a role in every major disease ([@r1]), and there are clinical examples of drugs targeting glycosylation enzymes \[Zavesca in Gaucher\'s disease ([@r44]), zanamivir (Relenza) and oseltamivir (Tamiflu) in influenza ([@r35]), and migalastat in Fabry\'s disease ([@r44])\], suggesting that glycosylation enzymes may provide fallow ground for drug development. Multiple biological pathways governed by different miRNA often are involved in disease processes. Our approach enables these miRNA networks to be leveraged to yield the most critical enzymes to target in a disease state. Taking advantage of this concept will require a better map of glycogene--miRNA interactions ([@r8]). By using miRNA as a relatively simple proxy to decrypt which glycogenes, including encoding difficult-to-analyze structures (e.g., proteoglycans, glycolipids), are important in specific biological states, this work provides a decryption key for the functional glycocode.

Experimental Procedures {#s7}
=======================

Glycogene Target Analysis of miR-200f. {#s8}
--------------------------------------

Identification and visualization of miR-200f glycogene targets and construction of the regulatory network was performed as previously described ([@r7]) with the following exception: Only glycosyltransferases with an mirSVR score of −0.1 or less were considered ([@r18]).

Luciferase Reporter Assay. {#s9}
--------------------------

Luciferase reporter assays were performed as previously described using pLightSwitch-MT vector constructs (SwitchGear Genomics) ([@r8]). Plasmids containing glycogene 3′ UTRs were obtained from SwitchGear Genomics (B3GLCT) or were cloned from cDNA using standard methods. [Dataset S1](#d35e1631){ref-type="supplementary-material"} shows the primers and sequenced 3′ UTRs.

Cell Culture and TGF-β1 Treatment. {#s10}
----------------------------------

The MDA-MB-231 and A549 cell lines (Division of Cancer Treatment and Diagnosis Tumor Repository, National Cancer Institute) were grown in RPMI-1640 medium (Lonza) supplemented with 10% (vol/vol) FBS (Innovative Research) and 2 mM [l]{.smallcaps}-glutamine (Lonza) at 37 °C in 5% CO~2~. For TGF-β1 treatment, A549 cells were was seeded at a density of 500,000 cells in a 10-cm dish; 24 h later the medium was replaced with reduced FBS (5%) growth medium supplemented with 5 ng/mL human recombinant TGF-β1 (R&D; 240-B-002) or vehicle, and cells were cultured for additional 48 h.

Transfection of miRNA Mimics in MDA-MB-231 Cells. {#s11}
-------------------------------------------------

MDA-MB-231 cells were seeded in six-well plates (80,000 cells per well), cultured for 24 h, and transfected with miRNA mimics (50 nM) using Lipofectamine 2000 (Life Technologies). Cells were transfected again 72 h after the initial treatment and 6--12 h later were split into 2 × 60 mm dishes. Samples were harvested for protein or RNA extraction on day 7 posttransfection.

Western Blotting. {#s12}
-----------------

Lysates from cells lysed in cold RIPA buffer supplemented with protease inhibitors were subjected to standard Western Blot protocols ([@r8]). The primary antibodies were α-GAPDH (glyceraldehyde-3-phosphate dehydrogenase; 1:10,000), α-E-cadherin (1:1,000), α-ST6GALNAC5 (1:1,000), and α-Vimentin (1:10,000) from Abcam and α-B3GLCT (B3GALTL, 1:1,000) and α-ST3GAL5 (1:1,000) from Novus Biologicals. Secondary antibodies \[α-mouse-HRP (GAPDH) or α-rabbit-HRP (all others) (Bio-Rad)\] were used at 1:5,000. Blots were developed using SuperSignal West Pico (Thermo Scientific).

RNA Extraction and Real-Time qPCR. {#s13}
----------------------------------

Total RNA was extracted from samples as previously described ([@r8]). Glycogene profiling summarized in [Tables S3](#st03){ref-type="table"} and [S4](#st04){ref-type="table"} was obtained by using RT^2^ Profiler PCR Array Human Glycosylation (Qiagen) and Power SYBR Green (Life Technologies) using the manufacturers' protocols. Additional primers were designed using PrimerSelect or NCBI primer blast and were purchased from Integrated DNA Technologies ([Dataset S1](#d35e1631){ref-type="supplementary-material"}). All cycle threshold values (Ct) were obtained by using the LightCycler Roche 480 Second Derivative Max algorithm.

###### 

Expression profile of glycogenes not predicted to be targets of the miR-200 family in MDA-MB-231 cells treated with miR-200a, miR-200b, or scramble mimics

  miR-200a treatment    miR-200b treatment                                                         
  --------------------- -------------------- ---------------- --------------------- -------------- ----------------
  ***A4GNT***           **−1.41**            **7.2E-03**      ***A4GNT***           **−1.81**      **1.1E-03**
  ***AGA***             **−1.37**            **2.5E-03**      *AGA*                 −1.17          0.24
  *[B3GNT3]{.ul}*       [13.51]{.ul}         [5.8E-06]{.ul}   *[B3GNT3]{.ul}*       [67.80]{.ul}   [1.4E-05]{.ul}
  *B3GNT8*              −1.14                0.42             *B3GNT8*              1.01           0.95
  *B4GALT1*             −1.17                0.20             *B4GALT1*             −1.15          0.16
  *B4GALT2*             1.01                 0.97             *B4GALT2*             −1.02          0.92
  *B4GALT3*             1.21                 0.43             *B4GALT3*             1.32           0.19
  *B4GALT5*             1.11                 0.62             *[B4GALT5]{.ul}*      [1.61]{.ul}    [2.1E-02]{.ul}
  *C1GALT1C1*           −1.01                0.94             *C1GALT1C1*           1.02           0.80
  *EDEM1*               −1.07                0.59             *EDEM1*               −1.05          0.65
  *EDEM2*               −1.06                0.60             *EDEM2*               1.04           0.66
  *EDEM3*               1.02                 0.79             *EDEM3*               −1.10          0.23
  *FUCA1*               −1.09                0.31             *FUCA1*               −1.12          0.19
  *FUCA2*               −1.09                0.24             *FUCA2*               −1.03          0.61
  *FUT8*                1.20                 0.19             *FUT8*                −1.07          0.45
  *FUT11*               1.03                 0.79             *FUT11*               1.28           0.12
  *GALNT1*              1.15                 0.29             *GALNT1*              −1.12          0.30
  *[GALNT6]{.ul}*       [2.14]{.ul}          [3.7E-04]{.ul}   *[GALNT6]{.ul}*       [1.79]{.ul}    [9.9E-05]{.ul}
  *GALNT7*              −1.07                0.60             *GALNT7*              −1.09          0.39
  *GALNT8*              −1.69                0.21             *GALNT8*              −2.07          0.18
  *GALNT9*              −2.19                0.12             *GALNT9*              −1.90          0.17
  ***GALNT13***         **−1.16**            **2.4E-02**      *GALNT13*             1.03           0.63
  ***GALNTL1***         **−1.61**            **1.3E-02**      ***GALNTL1***         **−2.02**      **3.3E-03**
  *GALNTL5*             1.41                 0.69             *GALNTL5*             1.08           0.94
  *GALNTL6*             −2.06                0.12             ***GALNTL6***         **−3.08**      **4.8E-02**
  *GANAB*               −1.01                0.92             *GANAB*               −1.02          0.80
  ***GCNT1***           **−1.61**            **8.1E-05**      ***GCNT1***           **−1.63**      **4.0E-03**
  *GCNT3*               −1.18                0.35             *GCNT3*               1.49           0.23
  *GLB1*                −1.06                0.73             *GLB1*                −1.17          0.26
  *GNPTAB*              −1.15                0.19             *GNPTAB*              −1.03          0.84
  *GNPTG*               −1.15                0.26             *GNPTG*               −1.13          0.22
  *HEXA*                −1.11                0.36             ***HEXA***            **−1.14**      **9.1E-02**
  *HEXB*                −1.13                0.24             *HEXB*                −1.17          0.11
  *MAN1A1*              1.09                 0.54             *MAN1A1*              −1.14          0.45
  *MAN1A2*              1.02                 0.88             *MAN1A2*              −1.15          0.25
  *MAN1B1*              −1.06                0.56             *MAN1B1*              −1.08          0.41
  *MAN1C1*              −1.07                0.76             ***MAN1C1***          **−1.39**      **3.9E-02**
  *MAN2A1*              −1.06                0.23             *MAN2A1*              1.13           0.23
  *MAN2A2*              1.24                 0.41             *MAN2A2*              1.43           0.12
  *MAN2B1*              1.04                 0.89             *MAN2B1*              1.01           0.97
  ***MANBA***           **−1.21**            **5.5E-04**      ***MANBA***           **−1.22**      **1.5E-02**
  *MGAT1*               1.18                 0.36             *[MGAT1]{.ul}*        [1.37]{.ul}    [1.9E-02]{.ul}
  *MGAT4B*              1.13                 0.39             *MGAT4B*              1.13           0.17
  *MGAT5*               1.27                 0.32             *MGAT5*               1.31           0.25
  *MGAT5B*              −1.29                0.15             ***MGAT5B***          **−2.24**      **3.7E-03**
  *MOGS*                1.10                 0.63             *[MOGS]{.ul}*         [1.32]{.ul}    [9.2E-02]{.ul}
  *NAGPA*               −1.33                0.32             *NAGPA*               −1.40          0.20
  *NEU1*                −1.08                0.63             *NEU1*                1.25           0.10
  *NEU2*                1.43                 0.24             *[NEU2]{.ul}*         [1.62]{.ul}    [3.2E-02]{.ul}
  *NEU3*                −1.05                0.63             *[NEU3]{.ul}*         [1.24]{.ul}    [7.4E-02]{.ul}
  *NEU4*                −1.35                0.51             *NEU4*                −1.63          0.36
  *OGT*                 −1.09                0.50             *OGT*                 −1.02          0.88
  *POFUT2*              −1.14                0.18             ***POFUT2***          **−1.25**      **1.4E-02**
  *POMGNT1*             1.06                 0.71             *POMGNT1*             −1.05          0.59
  *POMT1*               −1.18                0.33             *POMT1*               −1.07          0.61
  *POMT2*               1.07                 0.66             *POMT2*               1.02           0.85
  *PRKCSH*              1.02                 0.86             *PRKCSH*              1.07           0.39
  ***ST3GAL1***         **1.19**             **5.6E-02**      *[ST3GAL1]{.ul}*      [1.21]{.ul}    [2.7E-02]{.ul}
  ***ST6GAL1***         **−1.60**            **8.5E-03**      ***ST6GAL1***         **−2.08**      **3.8E-04**
  *[ST6GALNAC1]{.ul}*   [4.57]{.ul}          [4.4E-02]{.ul}   *[ST6GALNAC1]{.ul}*   [9.10]{.ul}    [6.1E-03]{.ul}
  *ST8SIA3*             −1.11                0.91             *ST8SIA3*             −1.06          0.95
  ***ST8SIA6***         **−1.72**            **1.7E-02**      ***ST8SIA6***         **−3.13**      **1.8E-03**
  *UGGT1*               −1.03                0.87             *UGGT1*               −1.15          0.30
  *UGGT2*               −1.09                0.44             ***UGGT2***           **−1.18**      **9.3E-02**

MDA-MB-231 cells were treated with miR-200a, miR-200b, or scramble mimics (50 nM) for 7 d. qRT-PCR was performed using RT^2^ Profiler PCR Array Human Glycosylation (Qiagen). Fold change (miR-treated/scramble-treated) was calculated by taking the average relative expression of miR-treated samples (*n* = 4 independent experiments, normalized to GAPDH) over the average relative expression of the scramble-treated cells (*n* = 4 independent experiments, normalized to GAPDH). Where the fold change was less than 1, the negative inverse is shown. *P* values for treated vs. scramble were calculated using Student\'s *t*-test. Statistically significant (*P* ≤ 0.05) down-regulation is in bold type, and statistically significant up-regulation is underlined.

Gene Silencing. {#s14}
---------------

MISSION shRNA clones (Sigma Aldrich) were obtained as viral stocks from the shRNA Core at New York University Langone Medical Center. MDA-MB-231 cells were seeded at 80,000 cells per well in a six-well format and were transduced 24 h later with shRNA lentivectors (multiplicity of infection = 2) in medium containing 8 µg/mL Polybrene (Sigma Aldrich; see [Dataset S1](#d35e1631){ref-type="supplementary-material"} for shRNA sequences). After 48 h, the medium was replaced with selection medium (1 µg/mL puromycin). Cells were harvested for protein and RNA extraction as described in the text.

Scratch Assay. {#s15}
--------------

MDA-MB-231 cells were seeded at 80,000 cells per dish in 35-mm dishes. MiRNA treatment and gene silencing were performed as previously described. Confluent monolayers of cells were scratched on day 6 (miR-200f treatment) or day 5 (silencing) using a P200 tip, and the medium was replaced to remove floating cells. Images were acquired immediately after the scratch and 24 h later. Images were analyzed in ImageJ using the MiToBo plugin ([www2.informatik.uni-halle.de/agprbio/mitobo/index.php/Main_Page](http://www2.informatik.uni-halle.de/agprbio/mitobo/index.php/Main_Page)) to quantify the wound area at time 0 h and 24 h. The percent of wound closure was calculated for a minimum of three regions per replicate (for one of the scramble-treated biological replicates only one region was imaged) and was averaged for three biological replicates.
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